Multiple Myeloma Treatment Options: What the Research Shows

Research-informed explainer — last updated April 12, 2026

Multiple myeloma treatment has changed more in the last decade than in the previous four put together. Patients diagnosed today have access to drug combinations that were unavailable five years ago, and some patients who would once have had a median survival measured in months are living five, ten, or more years after diagnosis. The landscape is genuinely complex, but the core logic is knowable.

This article explains what multiple myeloma is, how it's diagnosed and staged, what treatment categories exist, and what the research shows about who benefits from each approach. It draws on work from hematologists at Mayo Clinic and Dana-Farber Cancer Institute — centers that have contributed to defining how plasma cell disorders are understood and managed.

What is multiple myeloma?

Multiple myeloma is a cancer of plasma cells — the B cells that normally make antibodies. In myeloma, a malignant plasma cell clone expands in the bone marrow, crowding out healthy blood-forming cells and producing abnormal proteins called M proteins (or paraproteins). Those proteins, and the myeloma cells themselves, damage the skeleton, kidneys, and immune system over time.

It is not curable for most patients with current therapies, but it is frequently treatable over long periods. The disease follows a pattern of response, plateau, relapse, and re-treatment — and each new generation of drugs has extended how long patients stay in remission.

The closest biological relative is AL amyloidosis, a condition where the abnormal immunoglobulin light chains produced by a plasma cell clone deposit in organs including the heart, kidneys, and nerves rather than accumulating as a tumor. Work by Mayo Clinic specialists defined the diagnostic criteria for AL amyloidosis organ involvement and how treatment response is measured — criteria that continue to guide management of both conditions [1].

Signs and symptoms

Myeloma is often found incidentally on bloodwork before it causes symptoms. When it does produce symptoms, the classic pattern is remembered with the acronym CRAB:

• C — Calcium elevated (hypercalcemia), causing fatigue, confusion, or constipation
• R — Renal dysfunction (kidney damage from light chains or calcium)
• A — Anemia (low red blood cells), causing fatigue and shortness of breath
• B — Bone disease, including pain, fractures, and lytic lesions visible on imaging

Some patients develop frequent infections because myeloma suppresses normal immunoglobulin production. Nerve symptoms such as tingling or weakness can occur if amyloid deposits form or if the spine is affected.

How it is diagnosed

Diagnosis requires demonstrating the presence of an abnormal plasma cell clone and one or more myeloma-defining events. The standard workup includes:

• Blood tests: complete blood count, comprehensive metabolic panel, serum protein electrophoresis (SPEP), serum immunofixation, serum free light chains
• 24-hour urine protein electrophoresis and immunofixation
• Bone marrow biopsy: to confirm the plasma cell percentage and obtain cytogenetics and FISH testing
• Imaging: whole-body PET-CT or MRI to evaluate for bone lesions and extramedullary disease

The distinction between smoldering myeloma (no organ damage yet) and active myeloma (organ damage or ultra-high-risk features) matters because treatment is generally started for active disease and can sometimes be deferred for smoldering myeloma.

Genetic features detected by FISH — particularly deletions of chromosome 17p, translocation t(4;14), and t(14;16) — inform risk stratification and can influence treatment choice. Standard-risk and high-risk myeloma behave differently and may be managed differently even with the same drug classes.

Treatment options

Induction therapy

Most patients who can tolerate it receive a triplet or quadruplet regimen to achieve the deepest possible remission before transplant or as ongoing therapy. The backbone of most frontline regimens includes a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide or thalidomide), and dexamethasone. A fourth agent — typically daratumumab, a monoclonal antibody targeting CD38 on myeloma cells — is increasingly added to frontline treatment.

Clinical data show that adding daratumumab to a standard lenalidomide/dexamethasone doublet substantially reduced the risk of disease progression or death compared to the doublet alone in newly diagnosed, transplant-ineligible patients [from published phase 3 data]. Quadruplet regimens that include daratumumab with bortezomib, lenalidomide, and dexamethasone have also improved the depth of response, including the rate of measurable residual disease (MRD) negativity — a lab measure of how completely the myeloma has been cleared from the bone marrow.

Autologous stem cell transplant

For patients under approximately 70 to 75 who are otherwise fit, autologous stem cell transplant (ASCT) remains the standard consolidation approach after induction therapy in the United States. The patient's own stem cells are collected, high-dose melphalan is given to wipe out as much residual myeloma as possible, and the stem cells are infused back to rescue the marrow.

ASCT does not cure myeloma, but it has consistently been shown to extend progression-free survival compared to continuing maintenance without transplant. After transplant, most patients receive maintenance therapy — typically lenalidomide — to delay relapse.

At relapse: building on what worked

Myeloma almost always comes back. The choice of therapy at relapse depends on how long the first remission lasted, what drugs were used before, and any toxicities the patient experienced. A triplet regimen is typically needed at relapse, and the combination varies with each successive relapse [from published guidelines] — a principle that reflects the ongoing development of new agents in this disease.

Isatuximab and elotuzumab are additional monoclonal antibodies active in relapsed myeloma. Venetoclax, which blocks BCL-2, shows activity specifically in patients whose myeloma carries the t(11;14) translocation. Selinexor is approved for some heavily pretreated patients.

Immunotherapy approaches parallel those developed in acute leukemias, where antibody-drug conjugates have produced high remission rates in relapsed/refractory settings [7] — the same principle applied with belantamab mafodotin and other BCMA-targeted drugs in myeloma.

CAR-T cell therapy in myeloma

Two CAR-T products targeting BCMA (B-cell maturation antigen) are now approved for relapsed/refractory multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Both use the same general process as CAR-T in lymphoma — collecting and engineering a patient's T cells, then infusing them after lymphodepleting chemotherapy.

Cilta-cel moved earlier in the treatment sequence after a randomized trial showed it significantly reduced the risk of disease progression or death compared to standard care in lenalidomide-refractory patients who had received at least one prior line of therapy. This represents one of the most significant shifts in myeloma management in recent years — CAR-T is now being evaluated in the second-line setting rather than being reserved for heavily pretreated patients.

Bispecific antibodies

The newest category of myeloma therapy is off-the-shelf bispecific antibodies — drugs that simultaneously bind to a target on myeloma cells and to CD3 on T cells, bringing the two together. Teclistamab and elranatamab target BCMA; talquetamab targets GPRC5D. These are approved for multiply relapsed/refractory myeloma and do not require cell collection or manufacturing, making them more immediately accessible than CAR-T.

What specialists are discovering

Current research is focused on moving the most effective agents earlier and on achieving MRD negativity as a durable state. Whether sustained MRD negativity translates to functional cure — a state where the disease is present at undetectable levels and does not progress — is being investigated in long-term follow-up studies.

The precision-medicine framework that has transformed AML — matching therapy to the molecular features of each patient's disease, as in the use of IDH2 inhibitors for IDH2-mutated AML [6] — is arriving in myeloma in the form of t(11;14) patient selection for venetoclax and genomic profiling to guide risk-adapted therapy.

Immune-mediated approaches have also expanded in B-cell malignancies broadly. Research defining the genomic drivers of Waldenström macroglobulinemia [2][3] and demonstrating superior progression-free survival with targeted BTK inhibitor combinations [4] reflects the same direction of travel: away from generic chemotherapy and toward therapies matched to specific molecular targets. Myeloma is further along this path than most blood cancers.

Questions to ask your doctor

• What are my high-risk cytogenetic features, and how do they change the recommended approach?
• Am I a candidate for autologous stem cell transplant? If not, why not, and how does that change the treatment plan?
• Should I start with a triplet or quadruplet induction regimen, and is daratumumab part of the plan?
• How will you assess whether I have reached MRD negativity, and does that change what happens next?
• At what point would CAR-T or a bispecific antibody be considered in my treatment sequence?
• If my myeloma has the t(11;14) translocation, is venetoclax an option at relapse?
• Are there clinical trials that would be appropriate at this stage of my disease?

The bottom line

Multiple myeloma is treatable but not yet curable for most patients. Treatment has become layered and sequential — induction, possible transplant, maintenance, relapse therapy — with an expanding roster of active agents at each step. The decisions about sequence, combination, and timing are genuinely complex and depend heavily on individual disease biology, prior treatments, and patient fitness.

The most important step for someone newly diagnosed or facing first relapse is seeing a specialist at a center that treats high volumes of myeloma patients. The pace of change in this disease is fast enough that what was standard of care three years ago may no longer be the best available option today.